PRASAD SUYASH 4
4 · Taysha Gene Therapies, Inc. · Filed Feb 25, 2022
Insider Transaction Report
Form 4
PRASAD SUYASH
CMO and Head of R&D
Transactions
- Award
Employee Stock Option (right to buy)
2022-02-23+80,650→ 80,650 totalExercise: $5.96Exp: 2032-02-23→ Common Stock (80,650 underlying)
Footnotes (1)
- [F1]25% of the total number of shares underlying the option shall vest and become exercisable on February 23, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.